

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
09 November 2024 :: Issue 774
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives

.....
.....

Polio – PHEIC

Second round of polio campaign in Gaza completed amid ongoing conflict and attacks: UNICEF and WHO

6 November 2024 *Joint News Release*

The second round of the polio vaccination campaign in the Gaza Strip was completed yesterday, with an **overall 556 774 children under the age of 10 being vaccinated with a second dose of polio vaccine, and 448 425 children between 2- to 10-years-old receiving vitamin A, following the three phases conducted in the last weeks.**

Administrative data confirm **around 94% of the target population of 591 714 children under the age of 10 years received a second dose of nOPV2 across the Gaza Strip**, which is a remarkable achievement given the extremely difficult circumstances the campaign was executed under. The campaign achieved 103% and 91% coverage in central and southern Gaza, respectively. However, in northern Gaza, where the campaign was compromised due to lack of access, approximately 88% coverage was achieved according to preliminary data.

An estimated 7000-10 000 children in inaccessible areas like Jabalia, Beit Lahiya and Beit Hanoun remain unvaccinated and vulnerable to the poliovirus. This also increases the risk of further spread of poliovirus in the Gaza Strip and neighbouring countries.

The end of this second round concludes the polio vaccination campaign launched in September 2024. This round also took place in three phases across central, south and northern Gaza under area-specific humanitarian pauses. While the first two phases proceeded as planned, the third phase in northern Gaza had to be temporarily postponed on 23 October because of intense bombardments, mass displacements, lack of assured humanitarian pauses and access.

After careful assessment of the situation by the technical committee, comprising the Palestinian Ministry of Health, World Health Organization (WHO), United Nations Children's Fund (UNICEF), and the United Nations Relief and Works Agency for Palestine Refugees (UNRWA), the campaign resumed on 2 November. However, the area under the assured humanitarian pauses comprising the campaign was substantially reduced, compared to the first round, as the access was limited to Gaza City. Due to hostilities, more than 150 000 people were forced to evacuate from North Gaza to Gaza City, which helped in accessing more children than anticipated.

Despite these challenges, and thanks to the tremendous dedication, engagement and courage of parents, children, communities and health workers, the phase in northern Gaza was completed...

To fully implement surveillance and routine immunization services, not just for polio but for all vaccine-preventable diseases, **WHO and UNICEF continue to call for a ceasefire**. Further, apart from the attack on the primary healthcare centre, the campaign underscores what can be achieved with humanitarian pauses. These actions must be systematically applied beyond the polio emergency response efforts to other health and humanitarian interventions to respond to dire needs.

.....

Polio this week 06 Nov 2024

Headlines

- The polio endgame and its challenges: click [here](#) to read an interview with Dr Hamid Jafari, Director for Polio Eradication in WHO's Eastern Mediterranean, where he offers a comprehensive overview of the current global epidemiology, challenges and what must happen to overcome remaining obstacles and achieve a lasting polio-free world.
- Health Ministers of the [G7](#) and [G20](#) reaffirmed their dedication to ending polio this month: "we recommit to ending... neglected tropical diseases and polio as public health threats...(G7)"; and, "we reaffirm our commitment to ending the epidemics of AIDS, tuberculosis, malaria and for polio eradication (G20)".

•

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: four WPV1 cases and 53 WPV1-positive environmental samples
- Algeria: two cVDPV2-positive environmental samples
- DR Congo: two cVDPV1 cases
- Ethiopia: one cVDPV2 case
- Niger: one cVDPV2 case and one cVDPV2-positive environmental sample
- Nigeria: seven cVDPV2 cases and one cVDPV2-positive environmental sample
- Senegal: one cVDPV2 case
- Yemen: two cVDPV2 cases

.....

.....

mPox – PHEIC

WHO - Multi-country outbreak of mpox, External situation report #42- 9 November 2024

Highlights

- **Since the last situation report, three additional countries have confirmed travel-related cases of clade Ib MPXV: the United Kingdom of Great Britain and Northern Ireland, Zambia and Zimbabwe.**
- For the first time, local transmission of clade Ib MPXV was reported outside of Africa, in the United Kingdom of Great Britain and Northern Ireland, where three (all) household members of the initial case (who had travelled to affected East African countries with clade Ib) were confirmed to have mpox.
- **The number of mpox cases in Africa shows a general rising trend**, driven mainly by cases reported from the Democratic Republic of the Congo, Burundi, and Uganda.
- As of 3 November 2024, Clade Ib monkeypox virus (MPXV) has been detected in six provinces in the Democratic Republic of the Congo: South Kivu, North Kivu, Kinshasa, Kasai, Tshopo and Tanganyika, with no new areas known to be affected since the last update. Additionally, 11 other countries have also reported clade Ib MPXV cases.
- In the Democratic Republic of the Congo, the overall number of new reported mpox cases appears to be plateauing in South Kivu, which is still reporting the most cases in the country. In other provinces there are mixed epidemiological trends, with a few hotspots often driving the increase in case reports. Testing challenges in several provinces in the country persist, hindering an understanding of the evolving epidemiology.
- Further details about the epidemic dynamics in the Democratic Republic of the Congo (DRC) and other countries can be found in the WHO mpox surveillance report, which now also displays subnational data for the DRC.
- **The first round of mpox vaccination has concluded in the Democratic Republic of the Congo, with around 51 500 people vaccinated** across six provinces: Equateur, South Kivu, Nord Kivu, Sankuru, Sud Ubangi and Tshopo.

- In Burundi, the epidemic continues to be driven by clade Ib, with more than 200 laboratory-confirmed cases reported in each of the last two weeks. The epidemic remains largely concentrated in and around the city of Bujumbura, with two main age groups primarily affected, similar to what is observed in South Kivu (young children <5 years and young adults between 20-29 years), suggesting similar epidemic dynamics.
- **The epidemic is rapidly expanding in Uganda**, where in the last week more than 100 new confirmed mpox cases were reported. Transmission is driven by close intimate contact, involving sexual contact and sex work networks. The vast majority of cases reported are among adults.
- Rwanda has also reported a rising number of cases affecting adults, most of whom reported sexual contact with a person with mpox.
- Mauritius reported its first-ever mpox case; clade information is not yet available.
- Regarding global guidance and tools, the mpox screening tool for rapid identification, notification and isolation of suspected cases at health facilities was published.
- **The Mpox Vaccines Access and Allocation Mechanism (AAM) endorsed the recommendation by an independent Technical Review Committee (TRC) to allocate 899 000 doses of MVA-BN vaccine to nine countries across the African region** that are affected by the current mpox surge: the Central African Republic, Côte d'Ivoire, the Democratic Republic of the Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa and Uganda.
- A third mpox diagnostic test, a near-point-of-care real-time PCR test, was listed for EUL on 25 October.
- **On 22 November 2024, WHO will convene the Emergency committee on mpox to advise the WHO Director-General if mpox continues to constitute a public health emergency of international concern.**

.....

Vaccine doses allocated to nine African countries hardest hit by mpox surge

Addis Ababa/Geneva/New York/Oslo, 5 November 2024 –

The Access and Allocation Mechanism for mpox (AAM) has allocated an initial 899,000 vaccine doses for nine countries across the African region that are hit hard by the current mpox surge. In collaboration with affected countries and donors, this decision aims to ensure that the limited doses are used effectively and fairly, with the overall objective to control the outbreaks.

The AAM principals from Africa Centres for Disease Control and Prevention (Africa CDC), the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi), UNICEF, and World Health Organization (WHO) approved the allocation, following the recommendations of an independent Technical Review Committee of the Continental Incident Management Support Team for mpox. The decision was informed by country readiness and epidemiological data.

The nine countries are the Central African Republic, Cote d'Ivoire, the Democratic Republic of the Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa and Uganda. The largest number of doses – 85% of the allocation — will go to the Democratic Republic of the Congo as the most affected country, reporting four out of every five laboratory-confirmed cases in Africa this year.

These doses come from Canada, Gavi, the Vaccine Alliance, the European Union (Austria, Belgium, Croatia, Cyprus, France, Germany, Luxemburg, Malta, Netherlands, Poland, Portugal and Spain, as well as the European Union Health Emergency Response Authority), and the United States of America...

In recent weeks, limited vaccination has begun in the Democratic Republic of the Congo and Rwanda. This allocation to the nine countries marks a significant step towards a coordinated and targeted deployment of vaccines to stop the mpox outbreaks.

For most countries, the rollout of mpox vaccines will be a new undertaking. Implementing targeted vaccination requires additional resources. Partners of the mpox AAM, set up last month, are working to scale up the response. Further allocations of vaccines are expected before the end of the year.

###

Key points of the vaccination approach under the global and continental strategic preparedness and response plans:

1. **Vaccine Availability: Over 5.85 million vaccine doses are expected to be available to the Mpox Vaccines AAM by the end of 2024,** including the nearly 900 000 allocated doses. The supply includes contributions from multiple nations and organizations, including 1.85 million dose donations of MVA-BN from the European Union, United States, and Canada, 500 000 doses of MVA-BN from Gavi utilizing the First Response Fund, 500 000 doses procured through UNICEF, as well as a further 3 million doses of the LC16 vaccine from Japan.
2. **Phased Vaccination Strategy:**
 - **Phase 1: Stop Outbreaks** – Focused on interrupting transmission through targeted vaccination of people at highest risk of infection including contacts of confirmed cases, healthcare workers, frontline responders, and key at-risk populations in areas with active human to human transmission.
 - **Phase 2: Expand Protection** – To protect more people at risk in affected communities, as additional doses of vaccine are available. It targets individuals at high risk of severe disease—based on local epidemiology—in affected areas, focusing on regions with the highest incidence of mpox. Special attention will be given to vulnerable populations, including those living with HIV, internally displaced persons, and refugees, due to their increased risk of severe outcomes.
 - **Phase 3: Protect for the Future** – Aimed at building population immunity to guard against future outbreaks as part of a longer-term mpox control programme.

The first phase targets the vaccination of approximately 1.4 million people at risk of infection by the end of 2024, with an initial 2.8 million doses of the MVA-BN vaccine to be allocated for this effort.

3. **Maximizing the impact of vaccines through strategic vaccination is crucial:** Implementing targeted vaccination approaches can reduce transmission by focusing on those at the highest risk of infection. This vaccination strategy prioritizes individuals at substantially higher risk of exposure, including close contacts—such as household members and sexual partners—of confirmed cases. A combination of prevention and control interventions are recommended to optimize the effectiveness of vaccination efforts.
4. **Demand planning for Phase 2:** Current demand forecasts for Phase 2 estimate the need to vaccinate at least an additional 10 million individuals to protect high-risk groups across Africa. The projection is based on current epidemiological data and emerging information on transmission patterns. These estimates will be updated as more data becomes available, and the outbreak trajectory evolves.
5. **Regulatory and policy updates:** The WHO Strategic Advisory Group of Experts (SAGE) recommends off-label use of vaccines for children and pregnant women in outbreak settings. Urgent action is required to expedite regulatory pathways for vaccine approval across affected countries, ensuring timely access for infants and children. Additionally, delivery support must be strengthened to address in-country vaccine delivery challenges and ensure efficient distribution.

.....

WHO, Africa CDC support 17 countries to develop mpox vaccination plans

9 November 2024

Brazzaville, Congo – World Health Organization (WHO) and Africa Centres for Disease Control and Prevention (Africa CDC) **experts gathered in Brazzaville this week with country representatives and partners to provide guidance for the development of targeted mpox vaccine preparedness and deployment plans to ensure that available doses are used efficiently.**

In anticipation of further mpox vaccine deliveries to the African region in the coming months, countries had requested support on identifying and mapping mpox hotspots, based on the local epidemiology and the planning of targeted vaccination strategies to reach at risk of mpox populations.

"Given the ongoing difficulties with bringing the outbreak under control using traditional public health measures, the need for effective mpox vaccine preparedness and deployment plans has become urgent. **With the mpox vaccine supply constraints, countries will need to develop very targeted deployment plans, guided by local epidemiology,"** said Dr Matshidiso Moeti, WHO Regional Director for Africa.

More than 120 participants from 17 countries along with partners from Gavi, the Vaccine Alliance, UNICEF, United States Centers for Disease Control and Prevention, United States Agency for International Development, and with support from Canada participated in the 5-7 November 2024 Regional Mpox Vaccine Preparedness and Deployment Plan Development meeting. During the meeting, WHO and Africa CDC experts provided countries with the most up to date information on current WHO recommendations and a set of tools to guide mpox vaccination plan development.

Both organizations have made concerted efforts to help countries acquire vaccines amid ongoing outbreaks. WHO added the MVA-BN vaccine to its prequalification list on 13 September 2024; and established an Access and Allocation Mechanism (AAM) to facilitate better access to vaccines, treatments and tests where they are most needed.

Mpox vaccine deployments were delayed on the continent and the supply is likely to remain limited in the near- to medium-term. However, recently 3 countries in the African Region – Rwanda, the Democratic Republic of the Congo, Nigeria received a total of 280 000 doses. Initial vaccination efforts have started in the Democratic Republic of the Congo and Rwanda and more than 50 000 doses have been administered...

WHO and Africa CDC, and other partners are working together in the Continental IMST to support countries to prepare for and respond to mpox outbreaks, not just through vaccination, but also in areas such as diagnostics, case management, risk communication and community engagement...

The regional meeting focused on support for the following countries: Burundi, Cameroon, Central African Republic, Côte d'Ivoire, Democratic Republic of the Congo, Gabon, Ghana, Guinea, Liberia, Kenya, Nigeria, Republic of Congo, South Africa, Tanzania, Uganda, Zambia and Zimbabwe.

.....

.....

Pandemic Accord

Twelfth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response

4 – 15 November 2024

09:00–12:30, 14:00–17:30 CET, Geneva, Switzerland

Webcast - Specific sessions can be viewed by selecting them in the menu field next to the player.

.....

WMA calls on Member States to adopt binding commitments on pandemic prevention, preparedness, and response

World Medical Association_Press Release

4th November 2024

At the start of the Twelfth meeting of the Intergovernmental Negotiating Body (INB12) on pandemic prevention, preparedness and response, taking place in Geneva, Switzerland, from 4-15 November, the World Medical Association calls on Member States to adopt binding commitments, ensuring equity and transparency.

WMA adopts Strengthened Statement on Pandemics and Epidemics ahead of WHO Negotiations for a Pandemic Accord

Two weeks ago, the World Medical Association (WMA), at its 75th General Assembly in Helsinki, Finland, adopted a revised Statement on Pandemics and Epidemics that calls for strengthened global health resilience, equitable access to healthcare, and an integrated One Health approach. This Statement informs the WMA's advocacy within ongoing WHO Pandemic Accord negotiations to create an effective, legally binding framework for pandemic prevention, preparedness, and response (PPPR).

Urgent Appeal at INB12

At the INB12 meeting that starts in Geneva today, the WMA calls on Member States to adopt binding commitments rooted in equity and transparency.

"We must seize this moment to enshrine health equity as the foundation of global pandemic policy," said Dr Jung-Yul Park, WMA Chair of Council. "An accord without equitable access to healthcare for all will leave the world vulnerable and unjustly divided."

"Civil society and medical associations must be core partners in our collective pandemic response. We urge leaders to adopt a framework that upholds these principles and prepares all communities for future health threats," said Dr Park.

The WMA stands with civil society in pressing for an agreement that promotes equitable access to countermeasures, technology transfer, and a One Health focus.

Addressing inequities in health systems that hinder effective pandemic response, the Statement urges collaborative action from health, governmental, and non-governmental sectors to ensure preparedness measures are equitable, reaching vulnerable populations.

Embracing a One Health Approach to Pandemic Preparedness

The WMA emphasizes a One Health approach that connects human, animal, and environmental health as essential to addressing root causes of pandemics, including climate change, ecosystem degradation, and socio-economic disparities. This framework seeks to foster resilient health systems that can respond to emerging infectious threats effectively.

Key Actions Urged by the revised WMA Statement

The updated Statement outlines critical measures for global and national leaders:

- Strengthen Global Pandemic Infrastructure: Equip WHO to lead in global health efforts, emphasizing coordinated, rapid responses to infectious threats.

- Advance Health Equity: Address health disparities by ensuring timely, equitable access to critical health resources, particularly in vulnerable communities.
- Engage Civil Society in Preparedness: Recognize civil society's role in PPPR by actively involving non-governmental organizations, healthcare professionals, and local communities, whose contributions are essential to sustainable, effective pandemic response.
- Combat Misinformation: Ensure consistent, accurate public health messaging to counter misinformation.
- Enforce Legal Accountability: Support robust legal frameworks that uphold international accountability in pandemic preparedness, reinforcing WHO's International Health Regulations and the proposed Pandemic Accord.

.....

Endemic Pathogens

[WHO study lists top endemic pathogens for which new vaccines are urgently needed](#)

5 November 2024

News release Geneva, Switzerland

A new World Health Organization (WHO) study published today in *eBioMedicine* **names 17 pathogens that regularly cause diseases in communities as top priorities for new vaccine development.** The WHO study is the first global effort to systematically prioritize endemic pathogens based on criteria that included regional disease burden, antimicrobial resistance risk and socioeconomic impact.

The study reconfirms longstanding priorities for vaccine research and development (R&D), including for HIV, malaria, and tuberculosis – three diseases that collectively take nearly 2.5 million lives each year...

The study also identifies pathogens such as Group A streptococcus and *Klebsiella pneumoniae* as top disease control priorities in all regions, highlighting the urgency to develop new vaccines for pathogens increasingly resistant to antimicrobials.

"Too often global decisions on new vaccines have been solely driven by return on investment, rather than by the number of lives that could be saved in the most vulnerable communities," said Dr Kate O'Brien, Director of the Immunization, Vaccines and Biologicals Department at WHO. "This study uses broad regional expertise and data to assess vaccines that would not only significantly reduce diseases that greatly impact communities today but also reduce the medical costs that families and health systems face."...

This new WHO global priority list of endemic pathogens for vaccine R&D supports the Immunization Agenda 2030's goal of ensuring that everyone, in all regions, can benefit from vaccines that protect them from serious diseases. The list provides an equitable and transparent evidence base to set regional and global agendas for new vaccine R&D and manufacturing, and is intended to give academics, funders, manufacturers and countries a clear direction for where vaccine R&D could have the most impact...

The findings of this new report on endemic pathogens are part of WHO's work to identify and support the research priorities and needs of immunization programmes in low- and middle-income countries, to inform the global vaccine R&D agenda, and to strategically advance development and uptake of priority vaccines, particularly against pathogens that cause the largest public health burden and greatest socioeconomic impact.

WHO Priority endemic pathogens list

Vaccines for these pathogens are at different stages of development.

Pathogens where vaccine research is needed

- Group A streptococcus
- Hepatitis C virus
- HIV-1
- *Klebsiella pneumoniae*

Pathogens where vaccines need to be further developed

- Cytomegalovirus
- Influenza virus (broadly protective vaccine)
- *Leishmania* species
- Non-typhoidal *Salmonella*
- *Norovirus*
- *Plasmodium falciparum* (malaria)
- *Shigella* species
- *Staphylococcus aureus*

Pathogens where vaccines are approaching regulatory approval, policy recommendation or introduction

- Dengue virus
- Group B streptococcus
- Extra-intestinal pathogenic *E. coli*
- *Mycobacterium tuberculosis*
- Respiratory syncytial virus (RSV)

.....
.....

Contents [click to move among sections]

[*:: Milestones, Perspectives*](#)

[*:: WHO*](#)

[*:: Organization Announcements*](#)

[*:: Journal Watch*](#)

[*:: Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 09 Nov 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

7 November 2024 *News release*

[WHO demands urgent integration of health in climate negotiations ahead of COP29](#)

7 November 2024 *News release*

[Countries pledge to act on childhood violence affecting some 1 billion children](#)

6 November 2024 *Joint News Release*

[Second round of polio campaign in Gaza completed amid ongoing conflict and attacks: UNICEF and WHO](#)

6 November 2024 *Joint News Release*

[Vaccine doses allocated to 9 African countries hardest hit by mpox surge](#)

5 November 2024 *News release*

[WHO study lists top endemic pathogens for which new vaccines are urgently needed](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 09 November 2024

[Rwanda begins countdown to declare Marburg outbreak over](#)

09 November 2024

[WHO, Africa CDC support 17 countries to develop mpox vaccination plans](#)

WHO Region of the Americas PAHO

:: 7 Nov 2024

[PAHO Director calls for urgent action to end violence against children in the Americas](#)

Globally, one in two children and adolescents experience some form of violence each year. In the Americas, the homicide rate among those under the age of 18 is the highest in the world. Bogotá, Colombia, November 7, 2024 (PAHO) — At the opening of the First Global Ministerial Conference on Ending Violence Against Children, Dr. Jarbas Barbosa,...

:: 7 Nov 2024

[PAHO joins Global Alliance Against Hunger and Poverty](#)

Washington D.C. 7 November 2024 (PAHO/WHO) – The Pan American Health Organization (PAHO) has joined the Global Alliance Against Hunger and Poverty, an initiative proposed by the Government of Brazil during its G20 Presidency to combat hunger and poverty worldwide. The Global Alliance against Hunger and Poverty aims to promote collective...

:: 6 Nov 2024

[PAHO Director and Colombian President strengthen health cooperation ties](#)

Bogotá, November 5, 2024 (PAHO) — The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, began a four-day official visit to Colombia on Tuesday with the aim of strengthening cooperation with the country. On his first day in Bogotá, Barbosa met with the President of the Republic, Gustavo Petro Urrego, accompanied by the...

:: 6 Nov 2024

[Malaria Day in the Americas: PAHO calls on expanded access to diagnosis and treatment](#)

Washington D.C. 6 November 2024 (PAHO/WHO) – On Malaria Day in the Americas, the Pan American Health Organization (PAHO) is urging countries, local leaders and partners in the fight against malaria to join forces to expand access to diagnosis and treatment to accelerate elimination. The slogan for Malaria Day in the Americas 2024: "Expanding access..."

:: 5 Nov 2024

[PAHO supports over ten countries in Latin America and the Caribbean to improve ethical governance of health research](#)

Washington, D.C., November 5, 2024 (PAHO) — In an effort to strengthen ethics in health research, the Pan American Health Organization (PAHO) is supporting more than ten countries in Latin America and the Caribbean in developing laws, regulations and policies to promote a robust ethical framework for research. This effort not only seeks to align...

WHO South-East Asia Region SEARO

:: 7 November 2024 *News release*

[Countries pledge to act on childhood violence affecting some 1 billion children](#)

WHO European Region EURO

:: 5 November 2024 *Media release*

First local transmissions of clade Ib mpox in the WHO European Region confirmed in the United Kingdom

WHO Eastern Mediterranean Region EMRO

:: **Sudan rolls out first malaria vaccines**

4 November 2024

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

Multi-country outbreak of mpox, External situation report #42- 9 November 2024

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

Multi-country outbreak of mpox, External situation report #42- 9 November 2024

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 45, pp. 653–676 8 November 2024

PDF: <https://iris.who.int/bitstream/handle/10665/379490/WER9945-eng-fre.pdf>

:: Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map

Health–Security Interface Technical Advisory Group (HSI-TAG): annual meeting summary

The Health–Security Interface Technical Advisory Group (HSI-TAG) was established by WHO to provide advice on bridging the public health and security sectors, also known as the Health–Security Interface (HSI), including preparedness and response to deliberate events (DEs) and potential DEs caused by chemical, biological, radiological and nuclear threats.

The HSI-TAG, first convened in 2019 and now acting under terms of reference updated in 2022, provides independent advice to WHO on topics, strategic priorities and plans of action related to the HSI. In accordance with the updated terms of reference and in response to formalization of the HSI-TAG, new members were appointed in an open selection. The 18 current HSI-TAG members have a wide breadth of expertise, including public health, defence and intelligence, chemical and biological preparedness and readiness, biosafety and biosecurity and risk communications. The Biosecurity and Health Security Protection (BSP) unit in the Epidemic and Pandemic Preparedness and Prevention Department of WHO serves as the secretariat to the HSI-TAG.

The annual meeting was convened in July 2024 to review progress and advance the work of WHO and the HSI-TAG...

Risks and benefits of emerging technology

A session was held on future directions in DE prevention and response, and in particular, **how the WHO secretariat and HSI-TAG can address the rapidly emerging risks and benefits of artificial intelligence (AI)**. The HSI-TAG agreed that AI poses significant risks, including ethical concerns, bias and potential misuse for creating biological weapons but also agreed that it had potentially transformative benefits for biomedical research and public health. **The group agreed that critical safeguards should be in place, such as agreement among developers to anticipate and mitigate risks, policy-makers to adopt legal frameworks and governance mechanisms, and researchers to fulfill education and training requirements...**

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

8 November 2024

[Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map](#)

7 November 2024

[Preventing HIV misdiagnosis: implementation guide](#)

7 November 2024

[Strengthening health systems to improve the health of displaced and migrant populations in the context...](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

[HHS Releases Sexually Transmitted Infections \(STIs\) Progress Report and Herpes Simplex Virus \(HSV\) Addendum to the STI National Strategic Plan](#)

November 7, 2024 News Release

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee December 12, 2024 Meeting Announcement - 12/12/2024](#)

CDC/ACIP [U.S.] [to 09 Nov 2024]

<http://www.cdc.gov/media/index.html>

Latest News

[Transcript for MMWR Telebriefing: Evidence of Recent H5 Bird Flu Infections among Dairy Workers and CDC Guidance Updates](#)

Nov 7, 2024

[ACIP Meetings](#)

Next ACIP Meeting
February 26-27, 2025

MMWR Weekly

<https://www.cdc.gov/mmwr/index2024.html>

November 7, 2024 / No. 44

[PDF of this issue](#)

- Personal Protective Equipment Use by Dairy Farmworkers Exposed to Cows Infected with Highly Pathogenic Avian Influenza A(H5N1) Viruses — Colorado, 2024
- Serologic Evidence of Recent Infection with Highly Pathogenic Avian Influenza A(H5) Virus Among Dairy Workers — Michigan and Colorado, June–August 2024

.....

.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[First certification of a veterinary vaccine platform technology master file](#)

Platform technologies enable rapid response to emerging infectious disease threats

8 November 2024

EMA's Committee for Veterinary Medicinal Products (CVMP) has issued the first certificate for a vaccine platform technology master file (vPTMF) which will support and accelerate the development and authorisation of new veterinary vaccines in the EU.

Vaccine platform technologies play an important role in animal and public health preparedness and the ability to respond to emerging animal and public health threats. They have a set of core components common to all vaccines based on the same platform, and can be adapted rapidly for use against emerging diseases.

The Innovax vPTMF certified by the CVMP is based on a turkey herpesvirus vector backbone. It is a retrospective certification as the platform is already used in several authorised vaccines indicated for active immunisation of one-day-old chicks or embryonated chicken eggs against relevant viral diseases. To submit marketing authorisation applications for new vaccines based on the same platform technology, the Innovax vPTMF certificate holder will have to generate and submit data not included in the vPTMF; generally, pertaining to the variant part of the platform that is specific for each individual vaccine.

The vPTMF certification system facilitates and expedites the approval of vaccines using the same platform technology. It allows developers to rapidly advance vaccine candidates in response to emerging health threats, as they can rely on the data already certified...

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

No new digest content identified.

.....

.....

Africa CDC [to 09 Nov 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

[WHO, Africa CDC support 17 countries to develop mpox vaccination plans](#)

9 November 2024

Stories

[New Guidance Sets Path to Strengthen AMR Surveillance](#)

8 November 2024

Stories

[Smallpox Drug in Clinical Trials for Treating Mpox in Africa](#)

8 November 2024

Stories

[Strengthening Immunisation in Eswatini](#)

8 November 2024

Stories

[Assessment Reveals Gaps in Risk Communication Preparedness in Member States](#)

8 November 2024

.....
.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 09 Nov 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 09 Nov 2024]

<http://english.nmpa.gov.cn/>

News

[NMPA signs letter of intent on cooperation with Danish Medicines Agency](#)

2024-11-04

Li Li, commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices in Beijing on Oct 24.

China CDC

[CCDC Weekly Reports: Current Volume \(6\)](#)

2024-11-08 / No. 45

[PDF of this issue](#)

No new digest content identified.

.....
.....

[Contents](#) [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 09 Nov 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 09 Nov 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 09 Nov 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 09 Nov 2024]

<https://carb-x.org/>

News

11.07.2024 |

[CARB-X applauds G20 Health Ministers' commitments to control antimicrobial resistance](#)

CARB-X is pleased to welcome the Rio de Janeiro Declaration of the G20 Health Ministers and the adjointed G20 Ministerial Declaration on Climate Change, Health and Equity and One Health, which were adopted at the G20 Health Ministerial Meeting in Rio de Janeiro on October 31.

CEPI – Coalition for Epidemic Preparedness Innovations [to 09 Nov 2024]

<http://cepi.net/>

CEPI News

News

[New study to assess mpox vaccine in pregnant women and infants](#)

The research could help expand vaccine access to these populations at risk of mpox complications but not currently eligible for vaccination.

6 Nov 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 09 Nov 2024]
<https://cioms.ch/>

News; Publications; Events

[CIOMS Glossary of ICH terms and definitions: Version 7 now available](#)

Version 7 of the CIOMS Glossary of ICH terms and definitions is now freely available [here](#). It can also be accessed from the ICH webpage [here](#).

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 09 Nov 2024]
<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 09 Nov 2024]
<https://dukeghic.org/>

News

[Issue 2: 7 November 2024 | Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox](#)

Welcome to the second issue of our biweekly report, "Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox." In this edition, we provide a comprehensive update on the latest developments and insights across all topic areas, featuring our most recent analyses and findings since the last issue. This report will be updated and shared every other week with our community. As always, we aim to serve as an external, independent source for tracking and catalyzing effective actions to meet and increase commitments, and to hold the key stakeholders to account for achieving emergency preparedness and response goals. [Access the full report.](#)

EDCTP [to 09 Nov 2024]
<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified

Emory Vaccine Center [to 09 Nov 2024]
<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 09 Nov 2024]
<http://www.euvaccine.eu/>

Latest News, Events

[PhD Researchers advancing malaria vaccine research with successful dissertation defences in MMVC project](#)

Two PhD students, Dr. Elizabeth Kibwana and Dr. Caroline Bundi, have successfully defended their dissertations under the Multi-Stage Malaria Vaccine Consortium (MMVC) project, advancing the fight against malaria through innovative research.
November 2024

Evidence Aid [to 09 Nov 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Evidence Aid: Final farewell – 31 October 2024

www.evidenceaid.org

When we announced the news of our closure back in July, we hoped that Evidence Aid summaries would remain accessible and free of charge beyond closure of the charity. We are delighted to be able to announce that from now, the International Rescue Committee are hosting the website, evidenceaid.org and continue to make much of Evidence Aid's existing material available to the public. Should you have any questions relating to the website after 31 October, please contact airbel@rescue.org.

Fondation Merieux [to 09 Nov 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 09 Nov 2024]

<https://www.gavi.org/>

Press Releases

Sudan rolls out first malaria vaccines

Port Sudan, 4 November 2024 – Sudan's Federal Ministry of Health, in partnership with the United Nations Children's Fund (UNICEF), the World Health Organization (WHO) and Gavi, the Vaccine Alliance, rolled out malaria vaccines for the first time in the country today to bolster efforts to protect children from the deadly disease.

The launch follows the arrival of the first consignment of 186,000 doses of malaria vaccines to Sudan in October. The vaccinations will begin today in health facilities in 15 localities in the Gedaref and the Blue Nile states, benefitting more than 148,000 children under the age of 12 months. In 2025 and 2026, the vaccine will be introduced in 129 localities across Sudan...

GE2P2 Global Foundation [to 09 Nov 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – October 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 16 Oct 2024 – Issue 24](#)

GHIT Fund [to 09 Nov 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

November 7, 2024

Approx. USD 4.0 M Invested in Product Development for NTDs - GHIT's First Investment in the Development of Diagnostics for Trachoma

Global Fund [to 09 Nov 2024]

<https://www.theglobalfund.org/en/news/>

News Releases

08 November 2024

Central African Republic Honors Global Fund with "Medal of Commandeur" for Lifesaving Work Against HIV, TB and Malaria

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) received the medal of "Commandeur" of the Central African Republic Order of Merit on 16 October from Faustin-Archange Touadéra, President of the Central African Republic, at Pa...

07 November 2024

Global Fund and Stop TB Step Up Collaboration to Fight Tuberculosis, the Biggest Infectious Disease Killer

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and the Stop TB Partnership yesterday signed a new collaboration framework with the aim of increasing momentum towards ending tuberculosis (TB) in low- and middle-income countr...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 09 Nov 2024]

<https://www.glopid-r.org/news/>

No new digest content identified.

Hilleman Laboratories [to 09 Nov 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 09 Nov 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 09 Nov 2024]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 09 Nov 2024]

<https://www.iavi.org/>

News, Features

IAVI at the 2024 ASTMH Annual Meeting

November 8, 2024

IAVI's strong presence at the TropMed conference will showcase the expansion of our emerging infectious diseases program and enable critical dialogue with our global health peers.

INSERM [to 09 Nov 2024]

<https://www.inserm.fr/en/home/>

Press Releases

[Global Reach: Inserm Celebrates in Washington, DC, 60 Years of Research and Innovation](#)

25 Oct 2024 |

In celebration of its 60th anniversary, Inserm is emphasizing its scientific collaboration with the United States and Canada. This privileged and fruitful relationship with North America will be highlighted during a day of scientific and institutional exchanges on October 29, 2024, at the French Embassy in Washington, DC. The event will be attended by Professor Didier Samuel, President and CEO of Inserm, along with representatives from numerous partner institutions. The agenda will include the initiation of new collaborations with leading American scientific institutions, the presentation of the 2024 Inserm International Award to a distinguished researcher, the strengthening of Inserm's presence in Washington, DC, and the launch of the Inserm Abroad Network.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

[Fostering regulatory collaboration to improve access to mpox medicines](#)

Global regulators discuss available knowledge supporting mpox medicine development and approval

25 October 2024

International regulators have published [a report](#) highlighting their considerations on the development, clinical trials and availability of vaccines and therapeutics for mpox. The report presents the outcomes of a workshop that was organised by EMA under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA).

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 09 Nov 2024]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

2 November 2024

[ICH Q9\(R1\) IWG Updated Training Materials](#)

The ICH Secretariat is pleased to announce the publication of the updated training materials related to ICH Q9(R1) Quality Risk Management (QRM).

ICRC [to 09 Nov 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[ICRC Statement: UN General Assembly Sixth Committee](#)

Statement 06-11-2024

[Sudan: ICRC President calls for greater humanitarian space and respect of international humanitarian law](#)

News release 06-11-2024

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 09 Nov 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 09 Nov 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 09 Nov 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 09 Nov 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 09 Nov 2024]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 09 Nov 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 09 Nov 2024]

<http://www.msf.org/>
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine - USA [to 09 Nov 2024]

<https://nam.edu/programs/News> [Selected]
No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 09 Nov 2024]

<https://www.nationalacademies.org/newsroom>
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 09 Nov 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

[National Vaccine Program Updates from the HHS Office of Infectious Disease and HIV/AIDS Policy](#)

The Office of Infectious Disease and HIV/AIDS Policy (OIDP) at the Department of Health and Human Services is in the process of developing the 2026 – 2030 national strategic plans for HIV, sexually transmitted infections, vaccines, and viral hepatitis. Our office also collaborates with the White House Office of HIV/AIDS Policy to develop the National HIV/AIDS Strategy.

We invite you to be part of this process as well as share this email with your networks. You can register for our November listening sessions at the links below.

Nov 13 Listening Session:

<https://roseliassociates.zoomgov.com/meeting/register/vJIItcuugqDMqHDP5OsXrBgghus2yN6GgFero>

November 14 Spanish Listening Session:

https://roseliassociates.zoomgov.com/meeting/register/vJIsdeqqqzsrHQ1mfReAcU99B_NjXEI207k#/registration

As a reminder, **the public comment period ends on December 6, 2024**, at 11:59 pm ET. Should you wish to provide comments, please submit them via the [online form](#). For more information about these activities, read the [Federal Register Notice](#)

NIH [to 09 Nov 2024]

<http://www.nih.gov/>
News Releases
No new digest content identified.

PATH [to 09 Nov 2024]

<https://www.path.org/media-center/>
Newsroom
No new digest content identified.

Sabin Vaccine Institute [to 09 Nov 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases
No new digest content identified.

UNAIDS [to 09 Nov 2024]

<http://www.unaids.org/en>

News, Stories, Updates

No new digest content identified.

UNICEF [to 09 Nov 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

News note 06 November 2024

Second round of polio campaign in Gaza completed amid ongoing conflict and attacks: UNICEF and WHO

EAST JERUSALEM/AMMAN/GENEVA/NEW YORK, 6 November 2024 - The second round of the polio vaccination campaign in the Gaza Strip was completed yesterday, with an overall 556,774 children under the age of ten being vaccinated with a second dose of polio vaccine, and 448,425 children between two- and ten-years-old recei...

Press release 06 November 2024

Vaccine doses allocated to nine African countries hardest hit by mpox surge

Addis Ababa/Geneva/New York/Oslo, 5 November 2024 - The Access and Allocation Mechanism for mpox (AAM) has allocated an initial 899,000 vaccine doses for nine countries across the African region that are hit hard by the current mpox surge. In collaboration with affected countries and donors, this decision aims to ...

Statement 05 November 2024

Statement by UNICEF Middle East and North Africa Regional Director Adele Khodr on the decimation of newborn care in the Gaza Strip

AMMAN, 5 November 2024 - "The Kamal Adwan Hospital in northern Gaza has become a besieged war zone. Its neonatal intensive care unit (NICU), the last remaining in the north, has reportedly been damaged in heavy attacks in recent days. "Access to the hospital is incredibly difficult but reports indicate that childr...

Unitaid [to 09 Nov 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 09 Nov 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 09 Nov 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 09 Nov 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 09 Nov 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update for Providers

October 2024

Announcements: December webinar, new RSV Q&A sheets, updated vaccine safety booklet, and new website section on vaccine ingredients

Wellcome Trust [to 09 Nov 2024]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 09 Nov 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 09 Nov 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 09 Nov 2024]

<https://www.wfpha.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 09 Nov 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

WMA calls on Member States to adopt binding commitments on pandemic prevention, preparedness, and response

4th November 2024

At the start of the Twelfth meeting of the Intergovernmental Negotiating Body (INB12) on pandemic prevention, preparedness and response, taking place in Geneva, Switzerland, from 4-15 November, the World Medical Association calls on Member States to adopt binding commitments, ensuring equity and transparency.

World Organisation for Animal Health [OIE] [to 09 Nov 2024]

<https://www.oie.int/>

Press Releases, Statements

Global Events

No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 09 Nov 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 09 Nov 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 09 Nov 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 09 Nov 2024]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 09 Nov 2024]

<https://ifpma.org/>

News, Statements [Selected]

Statement 6 Nov 2024

IFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers

The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.

On 31st October 2024, G20 countries published the Rio de Janeiro Declaration of the G20 Health Ministers.

Throughout their term as G20 President, Brazil has had a focus on a “resilient health systems” agenda, including achieving universal health coverage, strengthening health systems, and enhancing pandemic preparedness and response. The innovative pharmaceutical industry continues to be committed to supporting these priorities.

In April 2024, IFPMA, INTERFARMA, FIFARMA reiterated industry’s commitment to constructively engage and support the priorities of the G20 health agenda, including by advocating for:

- Preserving the policies and frameworks that enable health innovation;

- Improving our collective ability to prepare for and respond to future pandemics;
- Fostering a viable antibiotic R&D ecosystem;
- Promoting the convergence and harmonization of regulatory requirements; and
- Addressing neglected tropical diseases and climate change.

IFPMA, INTERFARMA and FIFARMA are pleased to see that the final Declaration seeks to address many of these priorities, with G20 countries:

- Supporting measures to achieve equitable access, including through healthcare systems strengthening; robust regulatory frameworks; and a skilled and a strong health workforce;
- Agreeing on “voluntary technology transfer on mutually agreed terms” for building collaborations;
- Strengthening pandemic preparedness and response, including supporting the Pandemic Fund and the conclusion of the Pandemic Treaty negotiations;
- Committing to address AMR, including welcoming the recent UN Political Declaration on AMR;
- Publishing a Ministerial Declaration on Climate Change and Health as well as a “One Health” approach, with measures to tackle reducing the impact of climate change on health, and on One Health, including on AMR.

Statement 4 Nov 2024

Twelfth meeting of the Intergovernmental Negotiating Body (INB)

On 4 November 2024 in Geneva, IFPMA delivered a statement at the twelfth meeting of the Intergovernmental Negotiating Body (INB).

Statement 2 Nov 2024

Conclusion of COP16 Negotiations on Multilateral Mechanism for Benefit-Sharing of DSI

On the conclusion of the COP16 negotiations on proposals to include digital sequence information (DSI) within the scope of the Convention of Biodiversity (CBD), IFPMA delivered a Statement

“The pharmaceutical industry has long supported the Convention on Biological Diversity’s objective to protect our natural world and will continue to engage in discussions on mechanisms that safeguard biodiversity while fostering scientific research and innovation”.

“The decision adopted today does not get the balance right between the intended benefits of such a mechanism and the significant costs to society and science that it has the potential to create”.

“The ability to rapidly use scientific data known as “digital sequence information” (DSI) is essential for developing new medicines and vaccines. Any new system should not introduce further conditions on how scientists access such data and add to a complex web of regulation, taxation and other obligations for the whole R&D ecosystem – including on academia and biotech companies. New technologies that use DSI can contribute to conservation and sustainable use of biodiversity and should be encouraged”.

“Ahead of COP17, it is critical that governments work to ensure the implementation of any new mechanism on digital sequence information does not stifle the medical research and innovation that can bring the next wave of medical progress to people around the world.”

International Alliance of Patients’ Organizations – IAPO [to 09 Nov 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 09 Nov 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified

Bavarian Nordic

Latest News - No new digest announcements identified

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

4 November 2024

- *Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech's FixVac platform*
- *Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trials*
- *Phase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122/RO7198457) as an adjuvant treatment in patients with high-risk muscle-invasive urothelial cancer...*

Boehringer

Press Releases - No new digest announcements identified

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News

November 4, 2024

[CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer](#)

November 4, 2024

[CureVac to Present at the 12th International mRNA Health Conference](#)

November 4, 2024

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

November 8, 2024

[Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older](#)

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified.

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified [English translation function inoperable]

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

[Home](#) - [Website not responding [404 error]]

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 4
<https://www.tandfonline.com/toc/uabr21/current>
[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 11: E823-895
<https://journalofethics.ama-assn.org/issue/peace-health-care>
Peace in Health Care

Clinicians are carefully trained to incorporate and routinize what they do together every day, over and over again: health care professionalism has always been and is a practice. While so-called “medical shows” glamorize high-stakes, emotional health care situations, skilled clinicians generally strive to mitigate crises and control any variables they can, restore homeostasis, and promote stability and wellness in the lives of ill, injured patients. As a culture, we probably do not benefit much when health care organizations are misappropriated and misrepresented as sites of dramatic entertainment. In reality, patients, their loved ones, and their clinicians need health care organizations to be places of peace. This theme issue investigates what it means to establish and maintain health care as an enterprise known less for stress and more for healing.

American Journal of Human Genetics

Nov 07, 2024 Volume 111 Issue 11p2307-2582
<https://www.cell.com/ajhg/current>
Articles

[Genetic liability estimated from large-scale family data improves genetic prediction, risk score profiling, and gene mapping for major depression](#)

Morten Dybdahl Krebs, et al.

Our method, the Pearson-Aitken Family Genetic Risk Score, estimates genetic liability in a proband from patterns of disease outcomes in their relatives. The method is flexible, and the resulting scores can be used for genetic classification, describing genetic etiology, and improving power for gene mapping.

American Journal of Infection Control

November 2024 Volume 52 Issue 11 p1227-1344
<http://www.ajicjournal.org/current>
[Reviewed earlier]

American Journal of Preventive Medicine

November 2024 Volume 67 Issue 5 p641-802
<https://www.ajpmonline.org/current>
[Reviewed earlier]

American Journal of Public Health

November 2024 114(11)
<http://ajph.aphapublications.org/toc/ajph/current>
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 5 (Nov 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-5.xml>

Articles

Knowledge of Human Monkeypox Virus Infection among Healthcare Providers and Associated Factors in Addis Ababa, Ethiopia

Sofonias Girma Bekele, et al.

Research Article

DOI: <https://doi.org/10.4269/ajtmh.24-0247>

Page(s): 1078–1081

Motivation, Cues to Action, and Barriers to COVID-19 Vaccine Uptake: A Qualitative Application of the Health Belief Model among Women in Rural Zambia

Kayla J. Kuhfeldt, et al.

Research Article

DOI: <https://doi.org/10.4269/ajtmh.24-0005>

Page(s): 1118–1126

Annals of Internal Medicine

October 2024 Volume 177, Issue 10

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 336 November 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/336/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 09 Nov 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 09 Nov 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 09 Nov 2024)

Genomic characteristics, disease outcome and heterologous vaccine effectiveness among cases with SARS CoV-2 infection

In the pursuit of global health security, continuous monitoring of vaccine effectiveness across various viral strains emerges as a crucial imperative. The emergence of SARS-CoV-2 major variants of concern (VOC...

Authors: Rowan Abuyadek, Mira Mousa, Jumana AlAzazi, Ahmed Al Romaithi, Francis Selvaraj, Habiba Alsafar, Nawal Al Kaabi and Farida Al Hosani

Citation: BMC Infectious Diseases 2024 24:1266
Content type: Research Published on: 8 November 2024

[Epidemic preparedness and response capacity against infectious disease outbreaks in 186 countries, 2018–2022](#)

Disruptive public health risks and events, including infectious disease outbreaks, are inevitable, but their effects can be mitigated by investing in prevention and preparedness. We assessed the epidemic prepa...

Authors: Paul Eze, Judith Chidumebi Idemili, Friday Onwubiko Nwoko, Nigel James and Lucky Osaheni Lawani

Citation: *BMC Infectious Diseases* 2024 24:1258
Content type: Research Published on: 7 November 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 09 Nov 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 09 Nov 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 09 Nov 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 09 Nov 2024)

[Reviewing the progress of infectious disease early warning systems and planning for the future](#)

Past reviews of infectious disease early warning systems have encountered some limitations, such as a focus on specific diseases or regions in certain studies and constraints imposed by time delays in others. ...

Authors: Ziqi Li, Fancun Meng, Bing Wu, Dekun Kong, Mengying Geng, Xintong Qiu, Zicheng Cao, Tiancheng Li, Yaqian Su and Suyang Liu

Citation: *BMC Public Health* 2024 24:3080
Content type: Systematic Review Published on: 7 November 2024

[The impact of COVID-19 on routine child immunisation in South Africa](#)

The COVID-19 pandemic disrupted immunisation programs worldwide, reversing gains that had brought vaccine-preventable diseases largely under control. This study explored the impact of COVID-19 on the uptake of...

Authors: Sangiwe Moyo, Anushka Ashok, Laura Myers, Rebecca Nyankieya, Saransh Sharma and Ram Prasad

Citation: *BMC Public Health* 2024 24:3077

Content type: Research Published on: 7 November 2024

Vaccine equity implementation: exploring factors influencing COVID-19 vaccine delivery in the Philippines from an equity lens

During the early phase of the COVID-19 vaccine rollout, low and middle-income countries (LMICs) were facing challenges in achieving equitable vaccine delivery. Few studies have contextualized global vaccine di...

Authors: Junqiang Zhao, Shishi Wu, Renz Andrew Rafal, Helena Manguerra, Quanfang Dong, Hongyu Huang, Lincoln Lau and Xiaolin Wei

Citation: *BMC Public Health* 2024 24:3058

Content type: Research Published on: 5 November 2024

Assessment of childhood vaccination hesitancy among syrian parents under temporary protection

Vaccination programs become increasingly crucial during migratory movements driven by conflict and other disruptions. This study aims to determine the prevalence of childhood vaccination hesitancy among Syrian...

Authors: Elif Nur Kocak, Betül Zehra Pirdal, Servet Yüce, Muhammed Atak, Hatice Kocak Alkan, Mihriban Aksoy and Osman Faruk Bayramlar

Citation: *BMC Public Health* 2024 24:3043

Content type: Research Published on: 4 November 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 09 Nov 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2024 - Volume 29 - 5

<https://ebm.bmj.com/content/29/5>

[Reviewed earlier]

BMJ Global Health

October 2024 - Volume 9 - 10

<https://gh.bmj.com/content/9/10>

[Reviewed earlier]

Bulletin of the Atomic Scientists

September 2024

<https://thebulletin.org/magazine/2024-09/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(11); 2024 Nov 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/471305/>

Article

Hamid Jafari: the polio endgame and its challenges

Bull World Health Organ. 2024 Nov 1; 102(11): 776–777. Published online 2024 Nov 1.
doi: 10.2471/BLT.24.031124
PMCID: PMC11500254

Abstract

Hamid Jafari talks to Gary Humphreys about the non-linear nature of progress toward polio eradication and the challenges faced in the last two polio-endemic countries in the world.

Cell

Oct 31, 2024 Volume 187 Issue 22 p6125-6414
<https://www.cell.com/cell/current>
50th Anniversary
[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 6 November 2024
<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 5 Pages: 1143-1351 November 2024
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>
[Reviewed earlier]

Clinical Therapeutics

October 2024 Volume 46 Issue 10 p727-824
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 21 Issue 6, December 2024
<https://journals.sagepub.com/toc/ctja/21/6>
Ethics

[Individualized clinical decisions within standard-of-care pragmatic clinical trials: Implications for consent](#)

Isabel M Astrachan, et al.

Research article First published April 27, 2024 pp. 671–680

[Design and implementation of community consultation for research conducted under exception from informed consent regulations for the PreVent and the PreVent 2 trials: Changes over time and during the COVID-19 pandemic](#)

Tom Gugel, et al.

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 09 Nov 2024]
[No new digest content identified]

Contemporary Clinical Trials

Volume 146 November 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/146/suppl/C>

[No new digest content identified]

The CRISPR Journal

Volume 7, Issue 5 / October 2024

<https://www.liebertpub.com/toc/crispr/7/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 10 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

December 2024 - Volume 37 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 09 Nov 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 3 Pages: 135-261 September 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 5 September 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 4 October 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/4>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 11 8 November 2024

<https://www.embopress.org/toc/14693178/current>

Science & Society 23 September 2024

[**AI-driven biology: rethinking experiments and computation: An interview with Michael Bronstein, DeepMind Professor of Artificial Intelligence at the University of Oxford and Founding Scientific Director of the Aithyra Institute of the Austrian Academy of Sciences.**](#)

Thomas Lemberger

Michael Bronstein outlines his vision for the new Aithyra Institute, which aims to transform biological sciences using AI, with a focus on developing novel approaches to data collection, model training, and hypothesis generation to advance research and improve human health.

Emerging Infectious Diseases

Volume 30, Number 11—November 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 48 September 2024

<https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 5 Pages: 1-42 September–October 2024

Enrolling invested parties in research :: Research on social networking sites

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 1 - Spring 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 5, October 2024

<https://academic.oup.com/eurpub/issue/34/5>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

November/December 2024 Volume 103, Number 6

<https://www.foreignaffairs.com/issues/2023/103/6>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 09 Nov 2024]

[No new digest content identified]

Genetics in Medicines

Volume 26, Issue 11 November 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/11>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 09 Nov 2024]
[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

Review Article

Strategies to address COVID-19 vaccine hesitancy in First Nations peoples: a systematic review

Adeline Tinessia, Katrina Clark, Madeleine Randell, Julie Leask & Catherine King

Article: 2384497

Published online: 04 Sep 2024

Rapid Communication

'Health Camp' model: a unique approach for child vaccination in non-state armed actor controlled, inaccessible geographies in Somalia

Mohamed Hussein Kahow, Salad Ahmed Halane, Asma Ali & Rashed Shah

Article: 2391598

Published online: 23 Aug 2024

Global Health: Science and Practice (GHSP)

Vol. 12, No. 5 October 29, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 09 Nov 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 09 Nov 2024]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

SPECIAL SECTION – COMMEMORATING 30 YEARS

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 9, November 2024

<https://academic.oup.com/heapol/issue/39/9>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 09 Nov 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 19-20 / October 2024

<https://www.liebertpub.com/toc/hum/35/19-20>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Oct 08, 2024 Volume 57 Issue 10 p2251-2482

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 09 Nov 2024]

[No new digest content identified]

Global burden of zoonotic infectious diseases of poverty, 1990–2021

The zoonotic infectious diseases of poverty (zIDPs) are a group of diseases contributing to global poverty, with significant impacts on a substantial population. This study aims to describe the global, regional...

Authors: Chao Lv, Yiwen Chen, Zile Cheng, Yongzhang Zhu, Weiye Chen, Nan Zhou, Yiming Chen, Yinlong Li, Wangping Deng, Xiaokui Guo, Min Li and Jing Xu

Citation: Infectious Diseases of Poverty 2024 13:82

Content type: Research Article Published on: 6 November 2024

International Health

Volume 16, Issue 6, November 2024

<https://academic.oup.com/inthealth/issue/16/6>

[New issue; No digest content identified]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

Special Issue on Inter-State Communications

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 10 (2024): October 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/117>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 5, October 2024

<https://academic.oup.com/ije/issue/53/5>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

Table of contents

[Reviewed earlier]

JAMA

November 5, 2024, Vol 332, No. 17, Pages 1409-1496

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

November 2024, Vol 5, No. 11

<https://jamanetwork.com/journals/jama-health-forum/issue>

New Directions for Population Health Science and Scholarship

Sandro Galea, MD, DrPH; Mohammed Abba-Aji, MD, MPH

open access

JAMA Health Forum. 2024;5(11):e244566. doi:10.1001/jamahealthforum.2024.4566

This JAMA Forum discusses the philosophy and ethics of population health, approaches that may improve the health of populations, ideas for improving decision-making for better health outcomes, and the partnerships needed to improve population health.

JAMA Pediatrics

November 2024, Vol 178, No. 11, Pages 1089-1234

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

JB I Evidence Synthesis

October 2024 - Volume 22 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

November 2024 Volume 75 Issue 5 p691-844

<https://www.jahonline.org/current>

Review Article

Evidence Gaps in Economic Evaluations of HIV Interventions Targeting Young People: A Systematic Review

Armand Zimmerman, et al.

Published online: August 13, 2024

p709-72

Original Articles

A Prospective Study of the Relationship of COVID-19 Vaccination to Menstrual Cycle Characteristics in Adolescent Girls

Laura A. Payne, et al.

Published online: August 16, 2024

p819-826

Journal of Artificial Intelligence Research

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 5 October 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-5>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

Journal of Development Economics

Volume 171 October 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/171/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 3, July 2024

<http://journals.sagepub.com/toc/jre/current>

Special Issues in Research and IRB/REC Functioning, Including the use of AI

[Reviewed earlier]

Journal of Epidemiology & Community Health

October 2024 - Volume 78 - 10

<https://jech.bmj.com/content/78/10>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 3 Pages: 469-687 September 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 2 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: Climate Justice and the Global Development Crisis.

Guest Editors: Anna Malavisi, Tom Hilde, and Krushil Watene

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 3, August 2024

<https://muse.jhu.edu/issue/52935>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 5 October 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 8 Pages: 1-3156 November 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

Journal of Medical Ethics

November 2024 - Volume 50 - 11

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

The Journal of Pediatrics

Volume 274 November 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/274/suppl/C>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

November/December 2024 - Volume 30 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Public Health Policy

Volume 45, issue 3, September 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-3>

[Reviewed earlier]

Journal of the Royal Society – Interface

November 2024 Volume 21 Issue 220
<https://royalsocietypublishing.org/toc/rsif/current>
Life Sciences–Mathematics interface
Research articles

Model-informed optimal allocation of limited resources to mitigate infectious disease outbreaks in societies at war

Vaibhava Srivastava, Drik Sarkar and Claus Kadelka

Published: 06 November 2024 Article ID: 20240575

Abstract

Infectious diseases thrive in war-torn societies. The recent sharp increase in human conflict and war thus requires the development of disease mitigation tools that account for the specifics of war, such as the scarcity of important public health resources. We developed a compartmental, differential equation-based disease model that considers key social, war and disease mechanisms, such as gender homophily and the replacement of soldiers. This model enables the identification of optimal allocation strategies that, given limited resources required for treating infected individuals, minimize disease burden, assessed by total mortality and final epidemic size. A comprehensive model analysis reveals that the level of resource scarcity fundamentally affects the optimal allocation. Desynchronization of the epidemic peaks among several population subgroups emerges as a desirable principle since it reduces disease spread between different subgroups. Further, the level of preferential mixing among people of the same gender, gender homophily, proves to strongly affect disease dynamics and optimal treatment allocation strategies, highlighting the importance of accurately accounting for heterogeneous mixing patterns. Altogether, the findings help answer a timely question: how can infectious diseases be best controlled in societies at war? The developed model can be easily extended to specific diseases, countries and interventions.

Journal of Travel Medicine

Volume 31, Issue 7, October 2024
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

Journal of Virology

Volume 98 Number 9 September 2024
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Nov 09, 2024 Volume 404 Number 10465 p1783-1896, e5
<https://www.thelancet.com/journals/lancet/issue/current>
Articles

Genetic sequencing analysis of monkeypox virus clade I in Republic of the Congo: a cross-sectional, descriptive study

Claude Kwe Yinda, et al.

Monkeypox virus clade I is endemic in several central African countries and characterised by an increase in disease severity and mortality. Since October, 2023, a large-scale mpox outbreak has emerged in DR Congo, and in March, 2024, the first individuals with mpox were reported outside the endemic areas in Republic of the Congo. We aimed to provide insight into the epidemic by sequencing samples obtained from individuals with mpox in Republic of the Congo.

Review

The 2024 report of the *Lancet* Countdown on health and climate change: facing record-breaking threats from delayed action

Marina Romanello, et al.

Despite the initial hope inspired by the 2015 Paris Agreement, the world is now dangerously close to breaching its target of limiting global multiyear mean heating to 1.5°C. Annual mean surface temperature reached a record high of 1.45°C above the pre-industrial baseline in 2023, and new temperature highs were recorded throughout 2024. The resulting climatic extremes are increasingly claiming lives and livelihoods worldwide.

The Lancet Child & Adolescent Health

Oct 2024 Volume 8 Number 10 p707-792, e12-e15

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Oct 2024 Volume 6 Number 10 e673-e771

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Oct 2024 Volume 12 Number 10 e1560-e1736

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Oct 2024 Volume 24 Number 10 p1059-1176, e602-e659

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Oct 2024 Volume 9 Number 10 e709-e830

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2024 Volume 12 Number 10 p743-836, e57-e64

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 11 November 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-11>

[New issue; No digest content identified]

Medical Decision Making (MDM)

Volume 44 Issue 8, November 2024

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 3 Pages: 517-821 September 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Nov 06, 2024 Volume 32 Issue 11 p3747-4162

<https://www.cell.com/molecular-therapy/current>

[New issue; No digest content identified]

Nature

Volume 635 Issue 8037, 7 November 2024

<https://www.nature.com/nature/volumes/633/issues/8037>

Editorial 06 Nov 2024

[Science communication will benefit from research integrity standards](#)

Uncertainty is a core tenet of science — researchers should be supported so they can communicate it with confidence to the public.

Nature Biotechnology

Volume 42 Issue 10, October 2024

<https://www.nature.com/nbt/volumes/42/issues/10>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 09 Nov 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 10, October 2024

<https://www.nature.com/ng/volumes/56/issues/10>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 10, October 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/10>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 10, October 2024

<https://www.nature.com/nm/volumes/30/issues/10>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 10, October 2024

<https://www.nature.com/nrd/volumes/23/issues/10>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 10, October 2024

<https://www.nature.com/nrg/volumes/25/issues/10>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 10, October 2024

<https://www.nature.com/nri/volumes/24/issues/10>

[Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 18 November 7, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 10 October 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 09 Nov 2024]

[Reviewed earlier]

Pediatrics

Volume 154, Issue Supplement 3 November 2024

<https://publications.aap.org/pediatrics/issue/154/Supplement%203>

Articles

[New issue; No digest content identified]

PharmacoEconomics

Volume 42, Issue 11 November 2024
<https://link.springer.com/journal/40273/volumes-and-issues/42-11>
[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 09 Nov 2024)

[Biomedical researchers' perspectives on the reproducibility of research](#)

Kelly D. Cobey, Sanam Ebrahimzadeh, Matthew J. Page, Robert T. Thibault, Phi-Yen Nguyen, Farah Abu-Dalfa, David Moher

Meta-Research Article | published 05 Nov 2024 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3002870>

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 09 Nov 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 09 Nov 2024)

[The complexities of global health negotiations: Power dynamics and the politics of the pandemic agreement](#)

Chiamaka P. Ojiako, Tamrat Shaweno, Nebiyu Dereje, Jackline Kiarie, Benjamin Djoudalbaye, Morenike Oluwatoyin Folayan, Maha El Rabbat, Amr Ahmed Ramadan, Jean Kaseya, Nicaise Ndembi

Opinion | published 07 Nov 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003841>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 09 Nov 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 09 Nov 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 09 Nov 2024]

[Acceptance of Human Papillomavirus \(HPV\) vaccine among the parents of eligible daughters \(9–15 years\) in Bangladesh: A nationwide study using Health Belief Model](#)

Mohammad Delwer Hossain Hawlader, Fahima Nasrin Eva, Md. Abdullah Saeed Khan, Tariful Islam, Umme Kulsum Monisha, Irin Chowdhury, Rifat Ara, Nur-E-Safa Meem, Mohammad Ali Hossain, Arpita

Goutam, Tahmina Zerin, Nishat Alam, Rima Nath, Shamma Sifat, Sayla Sultana, Mosammat Sadeka Sultana, Sumit Kumar Saha, Naifa Enam Sarker, Mohammad Hayatun Nabi, Mohammad Lutfor Rahman
Research Article | published 08 Nov 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0310779>

Comparative analysis of state-level policy responses in global health governance: A scoping review using COVID-19 as a case

Fengyuan Tang, Wenqianzi Yang, Weijia Wu, Yewen Yao, Yi Yang, Qiyi Zheng, Baheti Maireyi, Shengxuan Jin, Hengjin Dong
Research Article | published 07 Nov 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0313430>

Exploring vaccine hesitancy in digital public discourse: From tribal polarization to socio-economic disparities

Huzeyfe Ayaz, Muhammed Hasan Celik, Huseyin Zeyd Koytak, Ibrahim Emre Yanik
Research Article | published 05 Nov 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0308122>

COVID-19 vaccine uptake and associated factors among individuals living in a peri-urban area in Uganda: A cross-sectional study

Mary Bridget Nanteza, Gertrude Nanyonjo, Nasimu Kyakuwa, Flavia Nakanjako, Hamza Kalute, Christine Atuhairwe, Christine Watera, Deogratius Ssemwanga
Research Article | published 04 Nov 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0312377>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 09 Nov 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

November 5, 2024 vol. 121 no. 45
<https://www.pnas.org/toc/pnas/121/45>
[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 10, October 2024
<https://academic.oup.com/pnasnexus/issue/3/10>
[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 3 - June 2024
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 187 October 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

November 2024 Volume 291 Issue 2034

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 235 Pages 1-218 (October 2024)

<https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 1-2, April/July 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 5, September/October 2024

<https://journals.sagepub.com/toc/phrg/139/5>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 12, October 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 4, October 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 09 Nov 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 44, Issue 10 Pages: 2313-2515 October 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 09 Nov 2024]

[No new digest content identified]

Science

Volume 386| Issue 6722| 8 Nov 2024

<https://www.science.org/toc/science/current>

Research Articles

[COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses](#)

BY Zhiyuan Chen, et al.

08 Nov 2024

Abstract

The global dynamics of seasonal influenza viruses inform the design of surveillance, intervention, and vaccination strategies. The COVID-19 pandemic provided a singular opportunity to evaluate how influenza circulation worldwide was perturbed by human ...

Science and Engineering Ethics

Volume 30, Issue 6 December 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-6>

[Authorship and Citizen Science: Seven Heuristic Rules](#)

Per Sandin, Patrik Baard, Gert Helgesson

Original Research/Scholarship Open access 29 October 2024 Article: 53

Science Translational Medicine

Volume 16| Issue 772| 6 Nov 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 09 Nov 2024]

[No new digest content identified]

Social Science & Medicine

Volume 358 October 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/358/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 09 Nov 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 5 October 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 61 September–October 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 10 Pages: i-iv, 849-921 October 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 25 14 November 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 09 Nov 2024]

Open Access Article

[Understanding Parental Decision-Making and Determinants of COVID-19 Vaccination for Children in Vietnam: A Cross-Sectional Online Survey](#)

by Hien T. Nguyen, Khanh C. Nguyen, Thai Q. Pham, Hieu T. Nguyen, Anh Hoang, Trang T. Vu, Huyen T. Nguyen, Nghia D. Ngu and Florian Vogt

Vaccines 2024, 12(11), 1266; <https://doi.org/10.3390/vaccines12111266> (registering DOI) - 8 Nov 2024

Abstract

Background/Objectives: In Vietnam, COVID-19 vaccination campaigns for children have encountered numerous challenges due to acceptance issues among parents. This study aimed to assess parental decision-making and identify factors influencing their decision to vaccinate their children against COVID-19. Methods: This was a cross-sectional online [...]

Open Access Article

Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations

by Darin Zehrung, Bruce L. Innis, Auliya A. Suwantika, Mahmoud Ameri, Robin Biellik, James C. Birchall, Alejandro Cravioto, Courtney Jarrahan, Lee Fairlie, James L. Goodson, Sonali Kochhar, Katrina Kretsinger, Christopher Morgan, Mercy Mvundura, Niraj Rathi, Edward Clarke, Jessica Joyce Mistilis, Marie-Chantal Uwamwezi, Birgitte Giersing and Mateusz Hasso-Agopsowicz
Vaccines 2024, 12(11), 1258; <https://doi.org/10.3390/vaccines12111258> - 6 Nov 2024

Abstract

Background: The Measles–Rubella Microarray Patch (MR-MAP) is an important technology that is expected to reduce coverage and equity gaps for measles-containing vaccines (MCVs), reach zero-dose children, and contribute to elimination of measles and rubella. MR-MAPs are anticipated to be easier to deploy [...]

Open Access Article

Lessons from Recent Measles Post-Campaign Coverage Surveys Worldwide

by M. Carolina Danovaro-Holliday, Mitsuki Koh, Claudia Steulet, Dale A. Rhoda and Mary Kay Trimner
Vaccines 2024, 12(11), 1257; <https://doi.org/10.3390/vaccines12111257> - 6 Nov 2024

Abstract

Background: Measles elimination strategies include supplementary immunization activities (SIAs) to rapidly fill immunity gaps. Post-campaign coverage surveys (PCCSs) are recommended to assess SIA coverage. We characterized selected PCCSs performed following recent SIAs, highlighting specific challenges and strengths, and provide recommendations for improvement.

Value in Health

November 2024 Volume 27 Issue 11p1469-1634

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

World Development

Volume 183 November 2024

<https://www.sciencedirect.com/journal/world-development/vol/183/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 09 Nov 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2411.03837

[A Temporal Playbook for Multiple Wave Dengue Pandemic from Latin America and Asia to Italy](#)

Alessandra D'Alise, Davide Iacobacci, Francesco Sannino

arXiv:2411.01080

[Submitted on 1 Nov 2024]

[Identifiability analysis of vaccination decision-making dynamics](#)

Azadeh Aghaeeyan, Mark A. Lewis, Pouria Ramazi

Variations in individuals' perceptions of vaccination and decision-making processes can give rise to poor vaccination coverage. The future vaccination promotion programs will benefit from understanding this heterogeneity amongst groups within a population and, accordingly, tailoring the communication strategies. Motivated by this, we developed a mechanistic model consisting of a system of ordinary differential equations that categorizes individuals based on two factors: (i) perceived payoff gains for vaccination and (ii) decision-making strategies where we assumed that individuals may behave as either myopic rationalists, going for a dose of vaccine if doing so maximizes their perceived payoff gain, or success-based learners, waiting to observe feedback on vaccination before deciding.

We then investigated the global identifiability of group proportions and perceived payoff gains, that is, the possibility of globally retrieving these parameters by observing the error-free cumulative proportion of vaccinated individuals over time.

To do so, for each group, we assumed a piecewise constant payoff gain and, for each time interval, obtained the so-called generalized input-output equation. We then proved the global identifiability of these parameters under certain conditions.

Global identifiability opens the door to reliable estimations of the group proportions and their perceived payoffs.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 09 Nov 2024]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 09 Nov 2024]

[Filter: All articles]

[A protocol for high-dose quadrivalent influenza vaccine effectiveness in the community and long-term care facilities using electronic health records](#)

Patrícia Soares, Verónica Gomez, Vânia Gaio, João Almeida Santos, Ana Paula Rodrigues, Ausenda Machado

medRxiv 2024.11.08.24316963; doi: <https://doi.org/10.1101/2024.11.08.24316963>

[Assessment of Vaccine managers' Knowledge and Observance of Vaccination Norms and Standards in an Urban Health District of Yaounde \(Cameroon\) during the COVID-19 Pandemic](#)

Fabrice Zobel Lekeumo Cheuyem, Adidja Amani, Brian Ngonheh Ajong, Raissa Katy Noa Otsali, Ariane Nouko, Edwige Omona Guissama, Christelle Sandrine Ngos, Adama Mohamadou, Guy Stephane Nloga,

Michel Franck Edzamba, Esther Andriane Bitye Bi Mvondo, Larissa Linda Ntsek, Christian Mouangue, Florence Kissougle Nkongo
medRxiv 2024.11.07.24316922; doi: <https://doi.org/10.1101/2024.11.07.24316922>

Exploring influenza vaccination coverage and determinants through digital participatory surveillance

Kathleen Kelley, Nicolò Gozzi, Mattia Mazzoli, Daniela Paolotti
medRxiv 2024.11.08.24316973; doi: <https://doi.org/10.1101/2024.11.08.24316973>

Factors associated with lower COVID-19 vaccine uptake among populations with a migration background in the Netherlands

Bente Smagge, Lisanne Labuschagne, Joyce Pijpers, Annika van Roon, Susan van den Hof, Susan Hahné, Hester de Melker
medRxiv 2024.11.07.24316886; doi: <https://doi.org/10.1101/2024.11.07.24316886>

Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis

Xiao Li, Lander Willem, Caroline Klint Johannesen, Arantxa Urchueguía-Fornes, Toni Lehtonen, Richard Osei-Yeboah, Heini Salo, Alejandro Orrico-Sánchez, Javier Díez-Domingo, Mark Jit, PROMISE investigators, Joke Bilcke, Harish Nair, Philippe Beutels
medRxiv 2024.08.06.24311440; doi: <https://doi.org/10.1101/2024.08.06.24311440> Revision

Optimal deployment of limited vaccine supplies to combat mpox

Matthew T Berry, C Raina MacIntyre, Deborah Cromer, Adam Hacker, Miles P Davenport, David S Khoury
medRxiv 2024.11.03.24316551; doi: <https://doi.org/10.1101/2024.11.03.24316551>

Abstract

Mpox outbreaks in Central Africa have been declared a public health emergency of international concern by the World Health Organization. Fortunately, real-world effectiveness studies of the MVA-BN vaccine indicate that it has an effectiveness of 74% after one dose, and 82% after two doses against mpox. However, given the very limited supply of vaccines in Central Africa, there remain questions around the optimal deployment of limited MVA-BN doses. In this study, we consider whether more mpox cases might be averted by following the traditional two-dose vaccine regimen (4 week dosing interval), or by giving a single dose of MVA-BN to as many individuals as possible. We find that the optimal strategy depends on both, (i) the degree to which a subpopulation might be at higher risk of mpox, or severe mpox, infections, and (ii) how long ago the first dose was administered to the most at-risk subpopulation.

Global estimates of lives and life-years saved by COVID-19 vaccination during 2020-2024

John P.A. Ioannidis, Angelo Maria Pezzullo, Antonio Cristiano, Stefania Boccia
medRxiv 2024.11.03.24316673; doi: <https://doi.org/10.1101/2024.11.03.24316673>

Risk Perception, Behavior, and Knowledge of Typhoid Fever Diagnosis, Treatment, and Vaccination: Insights from Patients in Kano, Nigeria

Nirmal Ravi, Oluwaseunayo Deborah Ayando
medRxiv 2024.11.04.24316691; doi: <https://doi.org/10.1101/2024.11.04.24316691>

Social inequalities in vaccine coverage and their effects on epidemic spreading

Adriana Manna, Márton Karsai, Nicola Perra
medRxiv 2024.11.01.24316556; doi: <https://doi.org/10.1101/2024.11.01.24316556>

COVID-19 disease and economic burden in adults in six Latin American Countries before nationwide vaccination program: Ministry of Health databases assessment and systematic literature review

Natalia Espinola, Cecilia I. Loudet, Rosario Luxardo, Carolina Moreno, Moe H. Kyaw, Julia Spinardi, Carlos Fernando Mendoza, Carolina M. Carballo, Ana Carolina Dantas, Maria Gabriela Abalos, Jamile Ballivian, Emiliano Navarro, Ariel Bardach

medRxiv 2024.10.31.24316541; doi: <https://doi.org/10.1101/2024.10.31.24316541>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7C%20Life%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 09 Nov 2024]

Open Letter Open Access

Considerations in planning a controlled human infection model in at-risk groups in sub-Saharan Africa: the case for pneumococcal challenge in people living with HIV in Malawi and a report of stakeholder consultation

[version 1; peer review: awaiting peer review]

Klara Doherty, et al.

Abstract

Controlled human infection models offer a unique opportunity to understand infectious disease pathogenesis and have accelerated vaccine development and evaluations in malaria and typhoid. One major limitation of most CHIMs is that they are typically conducted in healthy young adults who are generally the population least affected by infectious disease, and who exhibit distinct disease profiles to more at-risk populations such as people living with HIV, young children, and older adults. However, the added value of studying these populations with high relevance is only desirable if it can be done safely, robustly and acceptably. We present a framework to guide the conduct of a controlled human infection model in people living with HIV using a case-example of an experimental human pneumococcal carriage model in a setting of high disease-burden and transmission.

Plain language summary

Controlled human infection models (CHIMs) are a research method in which an infection is safely introduced into volunteer participants to better in order to understand the infection and test vaccines against it. These models are more efficient than traditional clinical studies because they require fewer participants. Most CHIMs have focused on healthy young adults, who are not the ones most affected by infectious diseases and have a distinct infection profile and vaccine response compared to population with a greater burden of infectious disease such as older adults and people living with HIV. Recently researchers have started to include these high-burden populations in CHIMs but safety and ethics are critical considerations before embarking on such studies. We propose a framework for safely and ethically conducting CHIMs in people living with HIV in order to advance research in this key population. We use a case example of a CHIM of pneumococcal carriage in the nose of people living with HIV in Malawi.

*

*

*

*

Think Tanks

Brookings [to 09 Nov 2024]
<http://www.brookings.edu/>
Research
No new digest content identified.

Center for Global Development [to 09 Nov 2024]
<https://www.cgdev.org/>
All Research
No new digest content identified.

Chatham House [to 09 Nov 2024]
<https://www.chathamhouse.org/>
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [to 09 Nov 2024]
<https://www.cfr.org/media/news-releases>
New Releases [Selected]
No new digest content identified.

CSIS [to 09 Nov 2024]
<https://www.csis.org/>
Reports [Selected]
No new digest content identified.

Kaiser Family Foundation [to 09 Nov 2024]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute [to 09 Nov 2024]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 09 Nov 2024]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 09 Nov 2024]
<https://www.pewresearch.org/>
Latest Publications [Selected]
No new digest content identified.

Rand [to 09 Nov 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

They Will Come, You Must Build It: A Modified Delphi Process Applied to Preparing Acute Care Facilities Infrastructure for High-Consequence Infectious Diseases

We developed consensus statements to inform recommendations for the design, maintenance, and operation of isolation spaces for patients with suspected or confirmed high-consequence infectious diseases.

Nov 4, 2024

Integrating Behavioral Health Into Monitoring and Surveillance During Public Health Emergencies: Challenges and Opportunities

Public health agencies have opportunities to strengthen behavioral health surveillance in public health emergencies and build partnerships to act based on timely, geographically granular existing data.

Nov 4, 2024

Effects of Non-Pharmaceutical Interventions on COVID-19 Transmission: Rapid Review of Evidence from Italy, the United States, the United Kingdom, and China

This study documents the magnitude and variation in NPI effectiveness in reducing COVID-19 transmission (i.e., reduction in effective reproduction rate [R eff] and daily contact rate) in Italy, the United States, the United Kingdom, and China.

Nov 4, 2024

Urban Institute [to 09 Nov 2024]

<https://www.urban.org/publications>

New Research Publications - Selected

World Economic Forum [to 09 Nov 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

Public Consultations/Call for Inputs/Call for Papers

Request for Information (RFI): To Inform the Development of the 2026-2030 National HIV/AIDS Strategy and the National Strategic Plans for Sexually Transmitted Infections, Vaccines, and Viral Hepatitis

US Health and Human Services Department - 10/07/2024 **Comment period ends December 6, 2024.**

Online public consultation on the draft WHO guidance on the ethics of health research priority setting

WHO 6 November 2024

Deadline for submission: 1st December 2024 [11:59pm on Sunday, , Central European Time (GMT/UHC +1)]

Call for consultation

This guidance on the ethics of health research priority setting has been produced by the WHO Health Ethics and Governance Unit. The Unit convened a small expert writing group¹, which was tasked with consulting widely with stakeholder groups globally in drafting the guidance. The document aligns to the Unit’s commitment to promoting ethical research and responds to calls for greater equity in health research globally.

Decisions about the allocation of resources for health research are matters of ethical concern, since who is ultimately likely to benefit from future research depends on which populations, conditions, and modalities are prioritized. The draft document circulated in this consultation aims to provide guidance for incorporating ethical considerations into health research priority setting. Such guidance is intended to supplement existing technical guidance by detailing explicit and systematic ethical principles for priority setting. Going forward, the aim is also to incorporate key elements of this guidance into relevant technical and policy guidance.

This document is intended to be relevant to everyone who engages in decisions about which health research to conduct, including individual researchers and patients, as well as funders and government agencies. We are particularly cognizant that those with responsibility for research agendas and priority setting exercises may benefit from this guidance.

Objective of the consultation

The goal of this online, open public consultation is to gather feedback from stakeholders on the draft WHO guidance on the ethics of health research priority setting. Comments are invited in particular on overall clarity, usability, and any gaps in the ethical considerations developed in the document.

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*